Latest Agomab Therapeutics News & Updates

See the latest news and media coverage for Agomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Agomab Therapeutics (Agomab)

Clinical-stage biopharmaceutical company developing therapies for fibro-inflammatory diseases

agomab.com

Headquarters: Antwerp, Belgium
Founded year: 2017
Company type: Public company
Number of employees: 77–200
Industry: Pharmaceuticals

Last updated October 1

Latest news about Agomab Therapeutics (Agomab)

In short: Agomab dosed the first patient in its global Phase 2b NOV-ERA Crohn’s disease study.

Company announcements

October 1 Agomab

Agomab reports positive data from STENOVA study

Ontunisertib shows favorable safety and sustained disease control in fibrostenosing Crohn's patients. This supports launching the global NOV-ERA Phase 2b trial.

September 14 Agomab

Agomab Announces Positive Phase 1 Results for AGMB-447

The company initiated the Phase 2 INSPIRIA study design and submitted a Clinical Trial Application to treat Idiopathic Pulmonary Fibrosis.

August 6 Agomab

Agomab Reports Half Year 2026 Financial Results

Cash reached €252 million after IPO. R&D expenses rose to €23 million while net loss widened to €31 million. FDA alignment occurred for NOV-ERA study.

April 23 Agomab

Agomab reports full year 2025 financial results

It raised $208M in Feb 2026, held €116.5M year-end cash, expects runway into H1 2029, and plans Phase 2 starts with topline readouts in H2 2026.

Media coverage

September 30 BioSpace

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn's disease (FSCD) patients ---- Low annualiz...

September 13 BioSpace

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 ---- Pharmacokinetic profile confirms efficient lung restriction with low systemic ex ...

August 6 Markets Insider

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in...

June 4 Investing.com

Agomab prices IPO at $16 per share, aims to raise $200 million

Agomab Therapeutics NV (AGMB) priced its initial public offering at $16.00 per American Depositary Share, the Belgium-based biopharmaceutical company announced February 5.

Never miss news about Agomab

Track Agomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Agomab competitors & trending companies

Browse news for competitors to Agomab and other trending companies.